<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03836768</url>
  </required_header>
  <id_info>
    <org_study_id>DTRM_DTRMWXHS-12_004</org_study_id>
    <nct_id>NCT03836768</nct_id>
  </id_info>
  <brief_title>BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma</brief_title>
  <official_title>A Phase Ib Study of BTK Inhibitor DTRMWXHS-12 in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang DTRM Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang DTRM Biopharma</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Primary Objective is to evaluate the safety and tolerability of the DTRMWXHS-12 capsule
      in patients with relapsed/refractory MCL and recommend the dose and dosing method (RP2D) used
      in phase II study.

      The Secondary Objective is to evaluate the pharmacokinetics (PK) of multiple dose oral
      administration of DTRMWXHS-12 capsule in patients with relapsed/refractory MCL.

      The Exploratory Objective is to preliminarily evaluate the efficacy of DTRMWXHS-12 capsule in
      patients with relapsed/refractory MCL.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 11, 2019</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Incidence and severity of (serious) adverse events n each patient according to the NCI-CTCAE4.03 grading</measure>
    <time_frame>Starting from date of first dose up to 35 days after last dose</time_frame>
    <description>To monitor AEs and SAEs in each patient according to the NCI-CTCAE4.03 grading criteria by evaluating changes in physical examination, laboratory tests, and 12-lead ECG during the whole study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>concentration of drug in plasma</measure>
    <time_frame>From date of first dose to day 56</time_frame>
    <description>concentration of drug in plasma</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>From date of first dose to date of disease progression, an average of 6 months</time_frame>
    <description>Percentage of patients with PR, CR</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Experimental Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DTRMWXHS-12, oral capsule, daily, 28 days as a cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTRMWXHS-12</intervention_name>
    <description>DTRMWXHS-12 capsules: 150 mg, 300 mg</description>
    <arm_group_label>Experimental Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. 18-75 Years old (include 18 and 75), gender is not limited.

          2. Measurable lesions by computed tomography (CT)/magnetic resonance imaging (MRI). A
             measurable lesion is defined as follows: at least the longest diameter of one lymph
             node &gt;1.5cm and clearly measurable in two vertical directions, or at least the longest
             diameter of one extranodal lesion &gt;1cm (e.g., liver nodule); If only spleen or
             gastrointestinal mucosa is involved, corresponding examinations and evaluations will
             be conducted in the investigator's opinion.

          3. The diagnosis report must contain morphology and evidence of positive cyclin D1 by
             immunohistochemistry or evidence of t (11; 14). The above results are tested by
             immunohistochemistry, cytogenetics or Fluorescent in situ hybridization (FISH). After
             enrollment, tumor tissue (FFPE) blocks or sections must be sent to the central
             laboratory for confirmation of MCL.

          4. The laboratory parameters are as follows:

               1. Hematology: Neutrophils ≥ 1.0×10^9/L without growth factor or blood transfusion,
                  platelets ≥ 75×10^9L (≥50×10^9/L if bone marrow is involved), and hemoglobins &gt;
                  9g/dL within 7 days before enrollment into the study.

               2. Liver: Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase
                  (SGOT) and alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase
                  (SGPT) ≤ 2.5×ULN; total bilirubin ≤ 2×ULN (&lt; 3×ULN when diagnosed as Gilbert's
                  syndrome).

               3. Kidney: Creatinine clearance≥30 ml/min (Evaluated by estimated glomerular
                  filtration rate [eGFR] according to the Cockcroft-Gault Equation or the
                  calculation equation of each site); Cockcroft-Gault equation= Female:
                  (140-age)×weight(kg)×0.85/(72×serum creatinine (mg/dL)) Male: (140-age)×body
                  weight(kg)/(72×serum creatinine(mg/dL))

               4. international normalized ratio(INR) ≤ 1.5×ULN and activated partial
                  thromboplastin time (APTT) ≤ 1.5×ULN, and for patients with acquired hemophilia
                  or those treated with clotting factor inhibitors or vitamin K antagonists, the
                  enrollment will be determined after discussion with the investigator.

          5. ECOG performance status score 0-2.

          6. Life expectancy &gt; 3 months.

          7. There must be documentations on relapsed or refractory lymphoma or disease progression
             after systemic therapy and at least one but less than five therapies for mantle cell
             lymphoma were administrated previously (1 ≤ number of previous therapies &lt; 5).

          8. No response with the last therapy (SD or PD during the treatment), or PD after the
             therapy.

          9. Patients with disease recurrence at least 3 months after autologous hematopoietic stem
             cell transplantation can be enrolled into the study, if there isn't any relevant
             active infection.

         10. Females of child-bearing potential must agree to use highly effective contraception
             methods during the study and at least 180 days after the last dose of the
             investigational drug. Highly effective contraception methods include abstinence,
             hysterectomy, bilateral ovariectomy without menstruation for six consecutive months,
             intrauterine contraception systems, hormonal contraception such as injectable
             contraceptives and oral contraceptives. Males must be sterilized via either vasectomy,
             or use barrier methods, while their female partners should take the effective
             contraception methods mentioned above.

         11. Patients are voluntary to sign the informed consent form and can understand and comply
             with all study requirements.

        Exclusion Criteria

          1. Patients suffering from or previously suffering from CNS lymphoma.

          2. Patients received other BTK inhibitors prior to enrollment. Patients who received
             steroid anti-tumor therapy (a dose equivalent to&gt;20mg/day of prednisone) within 7
             days, or received chemotherapy, targeted therapy, or radiotherapy within 4 weeks, or
             received anti-tumor Chinese medicinal herbs or antibody therapy within 4 weeks, prior
             to first administration of DTRMWXHS-12 capsule.

          3. Patients received major surgery in the past 4 weeks before screening (determined by
             the investigator according to the patient's condition).

          4. Patients with active bleeding or combination with anticoagulant therapy within 3-6
             months.

          5. Patients had undergone chemotherapy before and in whom the toxicity has not resolved
             (the toxicity has not resolved to ≤ grade 1 as per National Cancer Institute's Common
             Terminology Criteria for Adverse Events (CTCAE) Version 4.03, except for hair loss,
             absolute neutrophil count (ANC) and platelets). For neutrophils and platelets, please
             refer to the criterion 4 [Neutrophils] and [Platelets] in the inclusion criteria.

          6. Patients with a history of other active malignant diseases within 2 years prior to
             enrollment into the study, excluding the following: (1) adequately treated cervical
             carcinoma in situ; (2) local skin basal cell carcinoma or squamous cell carcinoma; (3)
             malignant diseases that has been controlled and completely locally treated (by surgery
             or other means)

          7. Patients suffering from active cardiovascular diseases with clinical significance,
             such as uncontrolled arrhythmia, congestive heart failure, Grade 3 or 4 heart disease
             according to New York Heart Association (NYHA) Functional Classification, or those
             with history of myocardial infarction within 6 months before screening.

          8. QTcF&gt;450 msecs or other significant ECG abnormalities, including second-degree
             atrioventricular block type Ⅱ, third-degree atrioventricular block.

          9. Patients who can't swallow capsules or with diseases significantly affect the
             gastrointestinal function, such as malabsorption syndrome, gastric or intestinal
             resection, symptomatic inflammatory bowel disease, or partial or complete intestinal
             obstruction.

         10. Uncontrolled systemic infections or infections requiring to be treated with
             intravenous antibacterial agents.

         11. Patients who previously received allogeneic stem cell transplantation.

         12. Patients known to have been infected with human immunodeficiency virus (HIV) or active
             hepatitis B or hepatitis C virus (polymerase chain reaction [PCR] or reverse
             transcription- polymerase chain reaction (RT-PCR) shows positive results).

         13. Hepatitis B test includes HBsAg, HBcAb and HBsAb. If the patient is HBsAg-negative but
             HBcAb-positive (regardless of HBsAb), the PCR technology will be used to detect
             hepatitis B virus (HBV) DNA, and the acceptable upper limit of normal in the table
             below is 1000 IU/mL. Considering different PCR kits may be used by different sites,
             the acceptable upper limit of normal for HBV DNA should be the normal value in the
             site. Hepatitis C test includes hepatitis C virus (HCV) antibody test, and if the HCV
             antibody is positive, the RT-PCR technology will be used to detect HCV RNA.

         14. Pregnant or lactating women.

         15. Any life-threatening disease, medical condition, or organ system dysfunction that, in
             the investigator's opinion, may affect subject safety or lead to study risks.

         16. Patients with poor compliance.

         17. Patients who receive treatment with a potent CYP3A (cytochrome P450, family 3,
             subfamily A) inhibitor or a potent CYP3A inducer within 7 days prior to enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei He, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Zhejiang DTRM Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 30, 2019</study_first_submitted>
  <study_first_submitted_qc>February 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2019</study_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

